Cancer-testis (CT) antigen expression in medulloblastoma Journal Article
| Authors: | Oba-Shinjo, S. M.; Caballero, O. L.; Jungbluth, A. A.; Rosemberg, S.; Old, L. J.; Simpson, A. J. G.; Marie, S. K. N. |
| Article Title: | Cancer-testis (CT) antigen expression in medulloblastoma |
| Abstract: | Medulloblastoma is the most common childhood malignant tumor of the central nervous system. Treatment of medulloblastoma requires harmful therapy and nevertheless carries a poor prognosis. Due to their presence in various cancers and their limited expression in normal tissues, CT antigens are ideal vaccine targets for tumor immunotherapy. CT antigens, such as MAGE and NY-ESO-1, have been employed in clinical trials in various malignancies but little is known about their presence in medulloblastoma. We analyzed 25 medulloblastomas for the expression of a panel of CT antigens by RTPCR and immunohistochemistry. Messenger RNA expression in the samples was as follows: GAGE 64%, MAGEA3/6 56%, SYCP1 44%, SLCO6A1 32%, MAGEC1 28%, MAGEC2 28%, MAGEA4 28%, NY-ESO-1 20%, MAGEA1 16%, and TPTE 0%. All cases except one (96%) were positive for mRNA expression of at least one CT gene. However, CT antigen expression was scarce on a protein level. Immunoreaction to monoclonal antibody E978 (NY-ESO-1) was negative in all cases; MA454 (MAGEA1), 57B (MAGEA4), M3H67 (MAGEA3/6), CT10#5 (MAGEC2) and #23 (GAGE) were each positive in 1 case, while the highest incidence of positive immunostaining, albeit heterogeneous, was seen with CT7-33 (MAGEC1) in 3 out of the 25 cases. The absence of correlation between mRNA and protein expression in medulloblastoma has not been observed in other tumors and further studies addressing the biology of CT antigens are necessary to investigate the present discrepant results. Copyright © 2008 by Suely K. N. Marie. |
| Keywords: | immunohistochemistry; adolescent; adult; child; clinical article; controlled study; human tissue; protein expression; human cell; genetics; antigen expression; metabolism; gene; cancer immunotherapy; reverse transcription polymerase chain reaction; incidence; neoplasm proteins; membrane proteins; pathology; tumor antigen; central nervous system tumor; monoclonal antibody; gene expression regulation; gene expression regulation, neoplastic; biosynthesis; immunology; antigens, neoplasm; cancer vaccine; cancer vaccines; messenger rna; rna, messenger; cancer testis antigen; melanoma antigen 1; ny eso 1 antigen; medulloblastoma; ctag1b protein, human; membrane protein; tumor protein; rna processing; tumor gene; cerebellar neoplasms; protein determination; testis; rna processing, post-transcriptional; rt-pcr; magec2 protein, human; major histocompatibility complex restriction; magea3 protein, human; cerebellum tumor; magea4 gene; magec1 gene; magec2 gene; magec1 protein, human; ct antigens; monoclonal antibody 23; monoclonal antibody 57b; monoclonal antibody ct10 5; monoclonal antibody e978; monoclonal antibody m3h67; monoclonal antibody ma454; ct gene; gage gene; magea 6 gene; magea3 gene; slco6a1 gene; sycp1 gene; tpte gene |
| Journal Title: | Cancer Immunity |
| Volume: | 8 |
| ISSN: | 1424-9634 |
| Publisher: | Academy of Cancer Immunology |
| Date Published: | 2008-04-22 |
| Start Page: | 7 |
| Language: | English |
| PUBMED: | 18426187 |
| PROVIDER: | scopus |
| PMCID: | PMC2935780 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 12" - "Export Date: 17 November 2011" - "Source: Scopus" |
Citation Impact
Related MSK Work